<?xml version="1.0" encoding="UTF-8"?>
<p id="p0065">Remdesivir, a 1′-cyano-substituted adenosine nucleotide analogue prodrug with broad-spectrum antiviral activity against several RNA viruses, may be evaluated.
 <xref rid="bib19" ref-type="bibr">
  <sup>19</sup>
 </xref> The first reported patient with COVID-19 infection in the United States was administered remdesivir. Based on worsening clinical status, IV remdesivir was given for compassionate use on hospital day 7 (illness day 11).
 <xref rid="bib20" ref-type="bibr">
  <sup>20</sup>
 </xref> Two randomized controlled trials have been registered to evaluate the safety and efficacy of remdesivir in mild/moderate or severe patients with COVID-19 viral pneumonia.
 <xref rid="bib21" ref-type="bibr">
  <sup>21</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib22" ref-type="bibr">
  <sup>22</sup>
 </xref> Kirchdoerfer and Ward
 <xref rid="bib23" ref-type="bibr">
  <sup>23</sup>
 </xref> noticed that nonstructural proteins (nsp)12 polymerase may be a template for the design of novel antiviral therapeutic agents to interrupt the assembly of the SARS-CoV core RNA-synthesis machinery. COVID-19 has full-length genome sequences with &gt; 75% nucleotide identity with that of SARS-CoV,
 <xref rid="bib7" ref-type="bibr">
  <sup>7</sup>
 </xref> which allows the molecular structure information to be used as a model for coronavirus antiviral design. Clinical studies should assess the effectiveness and safety of monoclonal and polyclonal neutralizing antibody products and aim to discover therapeutic targets against immunopathologic host responses.
</p>
